Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-08-28
2007-08-28
McKenzie, Thomas (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S265000
Reexamination Certificate
active
11385056
ABSTRACT:
The present invention describes compounds of Formula Ior a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal. The present invention also relates to a novel method of N-oxidation of nitrogen containing heteroaryls.
REFERENCES:
patent: 4187379 (1980-02-01), Butler
patent: 5028617 (1991-07-01), Lindel et al.
patent: 5481032 (1996-01-01), Pfirmann
patent: 5559113 (1996-09-01), Schwartz et al.
patent: 2002/0193398 (2002-12-01), Barrow et al.
patent: 2002/0198199 (2002-12-01), South et al.
patent: 2003/0158218 (2003-08-01), Nantermet et al.
patent: 2005/0070715 (2005-03-01), Bhat et al.
patent: 0379928 (1990-01-01), None
patent: 0516069 (1992-05-01), None
patent: 0516069 (1992-05-01), None
patent: WO 92/05271 (1992-04-01), None
patent: WO 93/14070 (1993-07-01), None
patent: WO 97/24122 (1997-07-01), None
patent: WO 99/45927 (1999-09-01), None
patent: WO 02/42272 (2002-05-01), None
patent: WO 2004/091613 (2004-10-01), None
Burgery, et al., Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines, Amer Chem Soc (2003), 46, pp. 461-473.
Burgery, et al., Pharmacokinetic Optimization of 3-Amino-6-chloropyrazinone Acetamide Thrombin Inhibitors. Implementation of P3 Pyridine N-Oxides to Deliver an Orally Bioavailable Series Containing P1N-Benzylamides, Bioorganic & Med Chem Letters 13 (2003) 1353-1357.
Caron, et al., A practical, efficient, and rapid method for the oxidation of electron deficient pyridines using trifluoroacetic anhydride and hydrogen peroxide-urea complex, Tetrahedron Letters 41 (2000) 2299-2302.
Euler, et al., Influence of physicochemical properties and intestinal region on the absorption of 3-fluoro-2pyrimidylmethyl 3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide, a water insoluble thrombin inhibitor, in dogs, International Journal of Pharmaceutics 275 (2004) 19-27.
Murata, et al., A Selective Procedure for 6-Substituted Pterin Derivatives: Synthesis and Substitution of Pterin 6- Triflate, Kluwer Academic Publishers 19-23 (2006).
Nantermet, et al., P2pyridine N-oxide thrombin inhibitors: a novel peptidomimetic scaffold, Bioorganic & Med Chem Letters (2005) 1-5.
Subramanian, et al., Bioactivation of the 3-Amino-6-Chloropyrazinone Ring in a Thrombin Inhibitor Leads to Novel DiHydro-Imidazole and Imidazolidine Derivatives: Structures and Mechanism Using13C-Labels, Mass Spectrometry, and NMR, The Amer Soc for Pharm and Experimental Therapeutics (2003) vol. 31 No. 11, 1437-1447.
Kreutter Kevin
Lee Yu Kai
Lu Tianbao
Player Mark
Teleha Christopher
Janssen Pharmaceutica N.V.
McKenzie Thomas
Robinson Binta
LandOfFree
Fluorinated pyridine N-oxide thrombin modulators and process... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fluorinated pyridine N-oxide thrombin modulators and process..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fluorinated pyridine N-oxide thrombin modulators and process... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3853442